RELL2
gene geneOn this page
Also known as FLJ90583
Summary
RELL2 (RELT like 2, HGNC:26902) is a protein-coding gene on chromosome 5q31.3, encoding RELT-like protein 2 (Q8NC24). Induces activation of MAPK14/p38 cascade, when overexpressed.
Predicted to enable collagen binding activity. Involved in positive regulation of p38MAPK cascade. Predicted to be located in basement membrane and plasma membrane.
Source: NCBI Gene 285613 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 8 total
- MANE Select transcript:
NM_173828
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26902 |
| Approved symbol | RELL2 |
| Name | RELT like 2 |
| Location | 5q31.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ90583 |
| Ensembl gene | ENSG00000164620 |
| Ensembl biotype | protein_coding |
| OMIM | 611213 |
| Entrez | 285613 |
Gene structure
Transcript identifiers
Ensembl transcripts: 8 — 5 protein_coding, 3 protein_coding_CDS_not_defined
ENST00000297164, ENST00000444782, ENST00000517794, ENST00000518025, ENST00000518856, ENST00000520674, ENST00000521367, ENST00000896721
RefSeq mRNA: 2 — MANE Select: NM_173828
NM_001130029, NM_173828
CCDS: CCDS4265
Canonical transcript exons
ENST00000297164 — 7 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001160506 | 141636997 | 141638409 |
| ENSE00002104435 | 141640671 | 141641064 |
| ENSE00003460119 | 141638955 | 141639021 |
| ENSE00003514338 | 141640412 | 141640445 |
| ENSE00003544561 | 141638795 | 141638860 |
| ENSE00003676392 | 141639920 | 141640295 |
| ENSE00003681668 | 141639464 | 141639649 |
Expression profiles
Bgee: expression breadth ubiquitous, 183 present calls, max score 92.00.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.8266 / max 162.4997, expressed in 1643 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 59050 | 5.3571 | 1563 |
| 59051 | 2.3565 | 859 |
| 59049 | 0.1129 | 40 |
Top tissues by expression
241 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right frontal lobe | UBERON:0002810 | 92.00 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 91.69 | gold quality |
| prefrontal cortex | UBERON:0000451 | 90.35 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 90.27 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 89.67 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 88.46 | gold quality |
| cerebellar cortex | UBERON:0002129 | 88.43 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 88.43 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 88.17 | gold quality |
| frontal cortex | UBERON:0001870 | 88.15 | gold quality |
| hypothalamus | UBERON:0001898 | 88.12 | gold quality |
| neocortex | UBERON:0001950 | 87.39 | gold quality |
| cerebellum | UBERON:0002037 | 87.22 | gold quality |
| adenohypophysis | UBERON:0002196 | 86.64 | gold quality |
| pituitary gland | UBERON:0000007 | 86.47 | gold quality |
| granulocyte | CL:0000094 | 85.68 | gold quality |
| nucleus accumbens | UBERON:0001882 | 85.59 | gold quality |
| cerebral cortex | UBERON:0000956 | 84.72 | gold quality |
| primary visual cortex | UBERON:0002436 | 84.65 | gold quality |
| substantia nigra | UBERON:0002038 | 84.32 | gold quality |
| putamen | UBERON:0001874 | 84.01 | gold quality |
| forebrain | UBERON:0001890 | 83.92 | gold quality |
| brain | UBERON:0000955 | 83.85 | gold quality |
| caudate nucleus | UBERON:0001873 | 83.74 | gold quality |
| midbrain | UBERON:0001891 | 82.70 | gold quality |
| pons | UBERON:0000988 | 82.06 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 81.79 | silver quality |
| occipital lobe | UBERON:0002021 | 81.40 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.36 | gold quality |
| cortical plate | UBERON:0005343 | 80.99 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7303 | no | 423.53 |
| E-ANND-3 | no | 1.20 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
27 targeting RELL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-2110 | 99.96 | 66.68 | 1930 |
| HSA-MIR-6753-3P | 99.93 | 66.57 | 637 |
| HSA-MIR-7107-3P | 99.93 | 66.73 | 627 |
| HSA-MIR-6721-5P | 99.93 | 68.92 | 2981 |
| HSA-MIR-4271 | 99.88 | 68.32 | 2244 |
| HSA-MIR-3065-3P | 99.87 | 70.25 | 1407 |
| HSA-MIR-383-3P | 99.85 | 65.84 | 1359 |
| HSA-MIR-4527 | 99.66 | 67.43 | 714 |
| HSA-MIR-6503-5P | 99.62 | 66.96 | 597 |
| HSA-MIR-4516 | 99.61 | 67.78 | 3390 |
| HSA-MIR-1207-5P | 99.49 | 69.11 | 2983 |
| HSA-MIR-6722-3P | 99.45 | 67.62 | 1919 |
| HSA-MIR-4763-3P | 99.10 | 67.83 | 2649 |
| HSA-MIR-1909-3P | 99.03 | 66.56 | 1662 |
| HSA-MIR-423-5P | 98.69 | 67.48 | 1522 |
| HSA-MIR-3184-5P | 98.56 | 67.13 | 1491 |
| HSA-MIR-581 | 98.39 | 67.42 | 835 |
| HSA-MIR-6511B-5P | 97.98 | 65.64 | 823 |
| HSA-MIR-6811-5P | 97.98 | 64.96 | 848 |
| HSA-MIR-10526-3P | 97.86 | 64.97 | 1342 |
| HSA-MIR-2861 | 95.24 | 65.47 | 1056 |
| HSA-MIR-1250-5P | 94.32 | 64.74 | 78 |
| HSA-MIR-6789-5P | 94.05 | 66.19 | 285 |
Literature-anchored findings (GeneRIF, showing 3)
- Binds to the TNF receptor family member RELT; homologue of RELT. (PMID:16389068)
- report that overexpression of RELT or its homologues RELL1 and RELL2 in HEK 293 epithelial cells results in cell death with morphological characteristics consistent with the activation of an apoptotic pathway. (PMID:19969290)
- Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis. (PMID:35634441)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rell2 | ENSDARG00000071876 |
| mus_musculus | Rell2 | ENSMUSG00000044024 |
| rattus_norvegicus | Rell2 | ENSRNOG00000019575 |
Protein
Protein identifiers
RELT-like protein 2 — Q8NC24 (reviewed: Q8NC24)
All UniProt accessions (3): E5RFS6, E5RHA7, Q8NC24
UniProt curated annotations — full annotation on UniProt →
Function. Induces activation of MAPK14/p38 cascade, when overexpressed. Induces apoptosis, when overexpressed.
Subunit / interactions. Interacts with RELT, RELL1 and OXSR1. Interacts with PLSCR1. Interacts with TRAF2.
Subcellular location. Cell membrane.
Tissue specificity. Primarily expressed in spleen, thymus, testis, peripheral blood leukocytes, brain and placenta. Not detected in prostate, ovary, small intestine, colon, heart, lung, liver, skeletal muscle, kidney and pancreas.
Post-translational modifications. Phosphorylated in vitro by OXSR1.
Similarity. Belongs to the RELT family.
RefSeq proteins (2): NP_001123501, NP_776189* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR022248 | TNF_rcpt_RELT | Family |
| IPR042313 | RELL2 | Family |
Pfam: PF12606
UniProt features (13 total): sequence variant 4, compositionally biased region 4, region of interest 2, chain 1, transmembrane region 1, modified residue 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8NC24-F1 | 60.01 | 0.08 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 52
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 79 (showing top):
RNGTGGGC_UNKNOWN, AP1_01, AAGCAAT_MIR137, SP3_Q3, AREB6_03, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, TGACCTY_ERR1_Q2, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, AP1_Q4_01, BACH2_01, GOBP_POSITIVE_REGULATION_OF_P38MAPK_CASCADE, TGANTCA_AP1_C, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION, GATA2_01
GO Biological Process (2): positive regulation of cell-substrate adhesion (GO:0010811), positive regulation of p38MAPK cascade (GO:1900745)
GO Molecular Function (2): collagen binding (GO:0005518), protein binding (GO:0005515)
GO Cellular Component (4): basement membrane (GO:0005604), plasma membrane (GO:0005886), membrane (GO:0016020), extracellular matrix (GO:0031012)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of cell-substrate adhesion | 1 |
| cell-substrate adhesion | 1 |
| positive regulation of cell adhesion | 1 |
| p38MAPK cascade | 1 |
| positive regulation of MAPK cascade | 1 |
| regulation of p38MAPK cascade | 1 |
| protein-containing complex binding | 1 |
| binding | 1 |
| extracellular matrix | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
| external encapsulating structure | 1 |
Protein interactions and networks
STRING
248 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RELL2 | OXSR1 | O95747 | 856 |
| RELL2 | CCDC15 | Q0P6D6 | 528 |
| RELL2 | TRAF1 | Q13077 | 506 |
| RELL2 | FCHSD1 | Q86WN1 | 447 |
| RELL2 | M1AP | Q8TC57 | 392 |
| RELL2 | XKR6 | Q5GH73 | 370 |
| RELL2 | ZDHHC16 | Q969W1 | 365 |
| RELL2 | RELT | Q969Z4 | 362 |
| RELL2 | CCHCR1 | Q8TD31 | 351 |
| RELL2 | PCDHGA6 | Q9Y5G7 | 314 |
| RELL2 | AKAP11 | Q9UKA4 | 311 |
| RELL2 | STK39 | Q9UEW8 | 301 |
| RELL2 | RELL1 | Q8IUW5 | 298 |
| RELL2 | PCDHGB6 | Q9Y5F9 | 284 |
| RELL2 | SRSF4 | Q08170 | 250 |
| RELL2 | SPZ1 | Q9BXG8 | 250 |
IntAct
69 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| OXSR1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.830 |
| RELL2 | OXSR1 | psi-mi:“MI:0915”(physical association) | 0.830 |
| RELL2 | OXSR1 | psi-mi:“MI:0914”(association) | 0.830 |
| ZNF32 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.590 |
| PLP1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ANKRD46 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC35A1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SEC22B | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC30A8 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| COL4A5 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ASPH | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TSPO2 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| NSG1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RELL2 | LPAR3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RTP2 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TSPAN33 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RELL2 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CDIPT | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZFPL1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MIP | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TFRC | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RELL2 | FAM3C | psi-mi:“MI:0915”(physical association) | 0.560 |
| SMIM1 | RELL2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RELL2 | ATP9A | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (68): RELL2 (Two-hybrid), TRIM9 (Affinity Capture-MS), OXSR1 (Affinity Capture-MS), LRR1 (Affinity Capture-MS), STK39 (Affinity Capture-MS), RELT (Affinity Capture-MS), AGBL5 (Affinity Capture-MS), MCM10 (Affinity Capture-MS), MGST2 (Affinity Capture-MS), HSPA14 (Affinity Capture-MS), DNAH14 (Affinity Capture-MS), SLC9A6 (Affinity Capture-MS), HADHB (Affinity Capture-MS), KIF2C (Affinity Capture-MS), C6orf120 (Affinity Capture-MS)
ESM2 similar proteins: A0A1B0GW64, A0A5F4BST2, A0PJX4, A8MVS5, A8MWV9, B0FP48, E5RIL1, E9PGG2, O14836, O60320, O95998, P09564, Q01113, Q01114, Q13477, Q2KI80, Q2T9R2, Q3TS39, Q3UPR0, Q3URD2, Q4V9L6, Q5FVJ4, Q5M869, Q6A044, Q6UWJ8, Q75VT8, Q864V4, Q8BRJ3, Q8BX43, Q8C503, Q8IVY1, Q8K5A9, Q8N112, Q8NC24, Q8NDY8, Q8QZT4, Q8R138, Q969Z4, Q9BUF7, Q9CQM1
Diamond homologs: Q08DP3, Q2KI80, Q5F3A4, Q5FVJ4, Q8BRJ3, Q8BX43, Q8IUW5, Q8K2J7, Q8NC24, Q969Z4, Q9N092, O95407, Q9HAV5, Q9NS68, Q9JLL3, Q8BX35
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 22 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Transport of small molecules | 5 | 9.7× | 1e-02 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
8 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 8 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1314 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 5:141638776:A:AG | acceptor_gain | 1.0000 |
| 5:141638786:A:AG | acceptor_gain | 1.0000 |
| 5:141638787:T:G | acceptor_gain | 1.0000 |
| 5:141638793:A:AG | acceptor_gain | 1.0000 |
| 5:141638794:G:GA | acceptor_gain | 1.0000 |
| 5:141638794:GCT:G | acceptor_gain | 1.0000 |
| 5:141638857:GAAG:G | donor_gain | 1.0000 |
| 5:141638861:G:C | donor_loss | 1.0000 |
| 5:141638861:G:GG | donor_gain | 1.0000 |
| 5:141638953:A:AG | acceptor_gain | 1.0000 |
| 5:141638954:G:GA | acceptor_gain | 1.0000 |
| 5:141638954:GC:G | acceptor_gain | 1.0000 |
| 5:141638954:GCC:G | acceptor_gain | 1.0000 |
| 5:141638954:GCCA:G | acceptor_gain | 1.0000 |
| 5:141638954:GCCAA:G | acceptor_gain | 1.0000 |
| 5:141639017:TCCAG:T | donor_loss | 1.0000 |
| 5:141639018:CCAG:C | donor_loss | 1.0000 |
| 5:141639019:CAGGT:C | donor_loss | 1.0000 |
| 5:141639020:AGGTG:A | donor_loss | 1.0000 |
| 5:141639022:GTGAG:G | donor_loss | 1.0000 |
| 5:141639023:T:A | donor_loss | 1.0000 |
| 5:141639623:G:T | donor_gain | 1.0000 |
| 5:141638405:GCCCC:G | donor_gain | 0.9900 |
| 5:141638410:G:GG | donor_gain | 0.9900 |
| 5:141638414:G:GG | donor_gain | 0.9900 |
| 5:141638777:A:G | acceptor_gain | 0.9900 |
| 5:141638790:TTCA:T | acceptor_loss | 0.9900 |
| 5:141638791:TCAG:T | acceptor_loss | 0.9900 |
| 5:141638792:CAG:C | acceptor_loss | 0.9900 |
| 5:141638793:A:C | acceptor_loss | 0.9900 |
AlphaMissense
1978 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 5:141638846:T:A | I79N | 1.000 |
| 5:141638846:T:C | I79T | 1.000 |
| 5:141638846:T:G | I79S | 1.000 |
| 5:141639921:T:C | F169L | 1.000 |
| 5:141639922:T:C | F169S | 1.000 |
| 5:141639922:T:G | F169C | 1.000 |
| 5:141639923:C:A | F169L | 1.000 |
| 5:141639923:C:G | F169L | 1.000 |
| 5:141638298:T:C | F25L | 0.999 |
| 5:141638300:C:A | F25L | 0.999 |
| 5:141638300:C:G | F25L | 0.999 |
| 5:141638310:G:C | G29R | 0.999 |
| 5:141638319:G:C | G32R | 0.999 |
| 5:141638320:G:A | G32D | 0.999 |
| 5:141638331:T:C | C36R | 0.999 |
| 5:141638332:G:A | C36Y | 0.999 |
| 5:141638341:T:A | L39H | 0.999 |
| 5:141638834:T:C | I75T | 0.999 |
| 5:141638834:T:G | I75S | 0.999 |
| 5:141638837:T:A | V76D | 0.999 |
| 5:141638855:A:T | N82I | 0.999 |
| 5:141638959:T:A | N85K | 0.999 |
| 5:141638959:T:G | N85K | 0.999 |
| 5:141638970:T:C | L89S | 0.999 |
| 5:141638979:T:C | M92T | 0.999 |
| 5:141639637:T:C | F164S | 0.999 |
| 5:141639646:G:T | G167V | 0.999 |
| 5:141639649:G:T | R168M | 0.999 |
| 5:141639921:T:A | F169I | 0.999 |
| 5:141639921:T:G | F169V | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000405355 (5:141635653 TCAACTCAGG>T), RS1000738666 (5:141635114 G>A,C,T), RS1001189800 (5:141635758 C>T), RS1001569293 (5:141636124 C>T), RS1001725897 (5:141640771 G>A), RS1002461059 (5:141639398 C>A,T), RS1003058177 (5:141637411 C>T), RS1003125029 (5:141638426 G>A), RS1003727280 (5:141637685 T>G), RS1003949336 (5:141640457 T>C,G), RS1004085355 (5:141640764 A>C,G), RS1004905288 (5:141637331 C>A,T), RS1005119858 (5:141636209 A>G), RS1005501041 (5:141635703 C>G), RS1006540758 (5:141637344 G>A)
Disease associations
OMIM: gene MIM:611213 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST010002_39 | Refractive error | 2.000000e-14 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
23 total (human), top 23 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases abundance, increases expression | 2 |
| tris(2-butoxyethyl) phosphate | affects expression | 1 |
| beta-lapachone | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| abrine | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| jinfukang | increases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Arsenic | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cisplatin | decreases expression | 1 |
| Plant Extracts | decreases expression, affects cotreatment | 1 |
| Smoke | decreases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Triclosan | increases expression | 1 |
| Urethane | decreases expression | 1 |
| Valproic Acid | increases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| Okadaic Acid | increases expression | 1 |
| Acrylamide | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.